Welcome to our dedicated page for Carlsmed news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on Carlsmed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Carlsmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Carlsmed's position in the market.
Carlsmed (NASDAQ:CARL), a medical technology company specializing in AI-enabled personalized spine surgery solutions, reported strong Q2 2025 financial results. Revenue reached $12.1 million, marking a 99% year-over-year growth. The company achieved a gross margin of 73.4% and reported a net loss of $6.8 million.
Key highlights include the successful completion of their first personalized cervical spine surgery using the aprevo® technology platform, and receiving CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures. The company maintains a strong financial position with $33.5 million in cash and recently raised $93.5 million through their IPO in July 2025.
Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-47.5 million, representing 67-75% growth over 2024.
Carlsmed (NASDAQ:CARL) reported strong Q2 2025 financial results, with revenue reaching $12.1 million, representing a remarkable 99% year-over-year growth. The company achieved a gross profit of $8.9 million with a 73.4% gross margin, though experiencing a slight decrease from 75% in Q2 2024.
Despite the revenue growth, Carlsmed reported a net loss of $6.8 million and an Adjusted EBITDA loss of $6.2 million. The company successfully completed its IPO in July 2025, raising $93.5 million in net proceeds. Looking ahead, Carlsmed projects full-year 2025 revenue between $45.5-$47.5 million, indicating 67-75% growth over 2024.
Notable achievements include the completion of their first personalized cervical spine surgery using the aprevo® technology platform and securing CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo® cervical procedures, effective October 2025.
Carlsmed (Nasdaq: CARL), a medical technology company focused on AI-enabled personalized spine surgery solutions, has scheduled its second quarter 2025 financial results announcement for August 28, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM Pacific Time on the same day. Participants are advised to register 5-10 minutes before the call begins. A replay will be available on the company's website following the event.
Carlsmed (NYSE:CARL) has secured CMS New Technology Add-On Payment (NTAP) approval for cervical fusion procedures using its aprevo® personalized interbody implants. Starting October 1, 2025, hospitals performing qualifying inpatient procedures with aprevo® devices will be eligible for up to $21,125 in additional reimbursement on top of standard Medicare payments.
The NTAP designation recognizes aprevo®'s significant clinical improvements over existing alternatives. The AI-enabled platform creates personalized implants matching each patient's unique anatomy, aiming to reduce revision surgeries. This approval follows the previous year's CMS reimbursement for Carlsmed's lumbar fusion devices. The company expects U.S. commercial launch in 2026, supported by FDA Breakthrough Device designation for cervical use.
Carlsmed (Nasdaq: CARL) has achieved a significant milestone with the first successful aprevo® cervical spine procedure performed on July 14, 2025, at UC San Diego Health. The procedure was conducted by Dr. Joseph Osorio, Chief of Spine Surgery in the Department of Neurological Surgery.
The aprevo® platform utilizes AI-powered surgical planning and digital production to create personalized spine devices that match each patient's unique anatomy and alignment requirements. The technology, which received FDA Breakthrough Device designation for cervical applications, is expected to launch commercially in the US in 2026.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company focused on AI-enabled personalized spine surgery solutions, has announced the pricing of its initial public offering. The company is offering 6.7 million shares at $15.00 per share, with trading expected to begin on July 23, 2025, on the Nasdaq Global Select Market.
The IPO is anticipated to generate gross proceeds of approximately $100.5 million before deducting underwriting costs and other expenses. Underwriters have a 30-day option to purchase up to an additional 1,005,000 shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, with Truist Securities and BTIG acting as joint book-runners.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company specializing in AI-enabled personalized spine surgery solutions, has announced its initial public offering. The company plans to offer 6.7 million shares of common stock with an expected price range of $14.00 to $16.00 per share.
The underwriters will have a 30-day option to purchase up to 1,005,000 additional shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, while Truist Securities and BTIG are acting as joint book-runners. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol "CARL".
FAQ
What is the current stock price of Carlsmed (CARL)?
What is the market cap of Carlsmed (CARL)?
